Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 17/20 | 0.47 |
| ▸ | JAK3 | P52333 | 17/20 | 0.47 |
| ▸ | JAK2 | O60674 | 13/20 | 0.47 |
| ▸ | JAK1 | P23458 | 13/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30147210 | 1.00 | GPR119 (0.47) | GPR119TYK2JAK3JAK2JAK1 | |
| SCHEMBL23878966 | 0.90 | TYK2 (0.50) | TYK2JAK3JAK2JAK1AURKA | |
| SCHEMBL23889558 | 0.89 | GPR119 (0.50) | GPR119TYK2JAK3JAK2JAK1 | |
| SCHEMBL22054196 | 0.89 | GPR119 (0.50) | GPR119TYK2JAK3JAK2JAK1 | |
| SCHEMBL23878810 | 0.89 | GPR119 (0.50) | GPR119TYK2JAK3JAK2JAK1 | |
| SCHEMBL23889580 | 0.88 | GPR119 (0.47) | GPR119TYK2JAK3JAK2JAK1 | |
| SCHEMBL30147216 | 0.88 | GPR119 (0.47) | GPR119TYK2JAK3JAK2JAK1 | |
| SCHEMBL22054065 | 0.86 | AURKA (0.53) | GPR119TYK2JAK3JAK2JAK1 | |
| SCHEMBL30147209 | 0.86 | AURKA (0.53) | GPR119TYK2JAK3JAK2JAK1 | |
| SCHEMBL22054573 | 0.86 | GPR119 (0.53) | GPR119TYK2JAK3JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| WO-2021238908-A1 | SALT AND CRYSTAL FORM OF HETEROARYL DERIVATIVE, AND PREPARATION METHOD THEREFOR | 上海翰森生物医药科技有限公司 | 2021-12-02 | — | — | WO | disclosed |
| WO-2020108613-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏豪森药业集团有限公司 | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, RORB | GPR119 1196/4885TYK2 105/4885JAK3 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.